

Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G18F0892C774EN.html>

Date: October 2022

Pages: 105

Price: US\$ 2,000.00 (Single User License)

ID: G18F0892C774EN

Abstracts

Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 13, 20 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 1, 1, 2 and 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Gliosarcoma - Overview

Gliosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gliosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gliosarcoma - Companies Involved in Therapeutics Development

A. Menarini Industrie Farmaceutiche Riunite Srl

Aettis Inc

Apexigen Inc

Arog Pharmaceuticals Inc

Bayer AG

Berg LLC

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CDG Therapeutics Inc

Chimerix Inc

Cothera Bioscience Pty Ltd

DNATRIX Inc

EpicentRx Inc

ERC Belgium SA

F. Hoffmann-La Roche Ltd

Fore Biotherapeutics Inc

Genexine Inc

Ipsen SA

Kazia Therapeutics Ltd

Kintara Therapeutics Inc

Lentigen Technology Inc

Merck & Co Inc
Merck KGaA
Mustang Bio Inc
Novartis AG
OncXerna Therapeutics Inc
Samus Therapeutics Inc
TheraBiologics Inc
Transtarget Inc
Vascular Biogenics Ltd
Vigeo Therapeutics Inc
Gliosarcoma - Drug Profiles
atezolizumab - Drug Profile
Product Description
Mechanism Of Action
avadomide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
bavituximab - Drug Profile
Product Description
Mechanism Of Action
CB-NK-TGF-betaR2 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
dianhydrogalactitol - Drug Profile
Product Description
Mechanism Of Action
efineptakin alfa - Drug Profile

Product Description
Mechanism Of Action
ERC-1671 - Drug Profile
Product Description
Mechanism Of Action
FORE-8394 - Drug Profile
Product Description
Mechanism Of Action
G-207 - Drug Profile
Product Description
Mechanism Of Action
icapamespib - Drug Profile
Product Description
Mechanism Of Action
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
LG-631 - Drug Profile
Product Description
Mechanism Of Action
lonafarnib - Drug Profile
Product Description
Mechanism Of Action
M-032 - Drug Profile
Product Description
Mechanism Of Action
marizomib - Drug Profile
Product Description
Mechanism Of Action
MB-108 - Drug Profile
Product Description
Mechanism Of Action
NU-0129 - Drug Profile

Product Description
Mechanism Of Action
ofranergene obadenovec - Drug Profile
Product Description
Mechanism Of Action
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
ONC-206 - Drug Profile
Product Description
Mechanism Of Action
P-28 - Drug Profile
Product Description
Mechanism Of Action
paxalisib - Drug Profile
Product Description
Mechanism Of Action
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
relatlimab - Drug Profile
Product Description
Mechanism Of Action
RRX-001 - Drug Profile
Product Description
Mechanism Of Action
sabatolimab - Drug Profile
Product Description
Mechanism Of Action
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
SL-701 - Drug Profile
Product Description
Mechanism Of Action
sorafenib tosylate - Drug Profile

Product Description
Mechanism Of Action
sotigalimab - Drug Profile
Product Description
Mechanism Of Action
tasadenoturev - Drug Profile
Product Description
Mechanism Of Action
TBX.OncV NSC - Drug Profile
Product Description
Mechanism Of Action
tepotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
troriluzole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
urelumab - Drug Profile
Product Description
Mechanism Of Action
vorinostat - Drug Profile
Product Description
Mechanism Of Action
VT-1021 - Drug Profile
Product Description
Mechanism Of Action
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
Gliosarcoma - Dormant Projects
Gliosarcoma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Gliosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gliosarcoma - Dormant Projects, 2022
Gliosarcoma - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Gliosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G18F0892C774EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G18F0892C774EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

